Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $241.37M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.10M
Average 0.12M
Income Statement
Follow revenue through to earnings.
Revenue
$16.38M
FY 2025 · Annual
+61.1% YoYOperating Income
-$41.98M
FY 2025 · Annual
Net Income
-$43.32M
FY 2025 · Annual
Income Statement
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.87M | 6.68M | 7.2M | 10.17M | 16.38M |
| Cost of Revenue | 3.92M | 3.66M | 2.82M | 3.47M | 4.79M |
| Gross Profit | 2.95M | 3.02M | 4.38M | 6.7M | 11.59M |
| Gross Margin | 43.0% | 45.2% | 60.9% | 65.9% | 70.8% |
| Research & Development | 15.28M | 14.69M | 14.38M | 16.15M | 20.96M |
| Selling, General & Admin | 17.97M | 17.93M | 18.62M | 22.02M | 32.61M |
| Operating Expenses | 33.24M | 35.15M | 33M | 38.17M | 53.57M |
| Depreciation & Amortization | 1.88M | 1.6M | 1.15M | 891.06K | 569.8K |
| EBITDA | (28.65M) | (26.6M) | (26.78M) | (25.59M) | (41.41M) |
| EBITDA Margin | -416.8% | -398.2% | -372.0% | -251.7% | -252.8% |
| Operating Income | (30.29M) | (32.13M) | (28.62M) | (31.47M) | (41.98M) |
| Operating Margin | -440.7% | -480.9% | -397.5% | -309.6% | -256.3% |
| Interest Income | 203.2K | 1.05M | 1.64M | 1.37M | 1.09M |
| Interest Expense | 66.41K | 167.11K | 770K | 0 | 0 |
| Other Income / Expenses | (303K) | 3.74M | (81K) | 4.99M | (1.08M) |
| Income Before Tax | (30.59M) | (28.38M) | (28.7M) | (26.48M) | (43.06M) |
| Pre-Tax Margin | -445.1% | -424.8% | -398.6% | -260.5% | -262.9% |
| Income Tax Expense | 105K | 287K | (128K) | (1.9K) | 256.41K |
| Net Income | (30.7M) | (28.67M) | (28.57M) | (26.48M) | (43.32M) |
| Net Margin | -446.7% | -429.1% | -396.8% | -260.4% | -264.4% |
| EPS (Basic) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| EPS (Diluted) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| 20.46M | 20.83M | 21.18M | 24.77M | 30.23M | |
| 20.47M | 20.83M | 21.18M | 24.77M | 30.23M |
PROF Earnings Waterfall · TTM
NASDAQ:PROF · Revenue to Net Income
Key Ratios
Analysis
$18.9M of revenue converted into -$39.2M of net income for the selected period. Gross margin is 71.5% and net margin is -282.4%, showing how much revenue survives after costs and taxes. EPS is $-1.25, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 8-K | Current report | Nov 3, 2026 |
How much revenue does PROF generate?
Profound Medical Corp. (PROF) reported $16.38M of revenue in fiscal 2025.
Is PROF profitable?
Profound Medical Corp. (PROF) reported -$43.32M of net income, with a net margin of -264.4%.
Continue the stock analysis
Jump to another research area for this company.